在胃癌中对抗HER2:当前的方法和未来的景观
Margherita Ratti1, Chiara Citterio1, Elena Orlandi1
1Oncology and Hematology Department, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy.
International journal of molecular sciences
|August 14, 2025
概括
特拉斯图祖马布德鲁克斯泰康对耐特拉斯图祖马布的HER2-阳性胃癌 (GC) 有希望. 新兴疗法向耐药机制,以改善HER2-阳性和HER2-低GC的治疗结果.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃癌 (GC) 是全球癌症死亡的主要原因.
- HER2 阳性 GC 是一个显著的子集,以 trastuzumab 为基础的化疗作为标准的第一线护理.
- 特拉斯图祖马布耐药性限制了治疗的有效性,需要新的治疗策略.
研究的目的:
- 审查当前和新兴的HER2导向治疗胃癌的方法.
- 为了突出特斯图祖马布在对特斯图祖马布耐药的HER2阳性GC中的疗效,deruxtecan.
- 讨论克服耐药性的策略,并扩大对低HER2群体的治疗.
主要方法:
- 对胃癌中HER2向治疗的临床试验和科学文献的综述.
- 对抗体药物合物 (ADCs),基于免疫的疗法和途径抑制剂的分析.
- 专注于trastuzumab deruxtecan及其在克服耐药性的作用.
主要成果:
- 特拉斯图祖马布德鲁克斯泰坎在HER2阳性GC中显示出显著的疗效,包括异质HER2表达和特拉斯图祖马布耐药性的病例.
- 其他针对HER2的ADC正在研究中,显示其作为替代治疗的潜力.
- 包括免疫疗法和途径抑制剂在内的新策略正在探索,以提高HER2-高和HER2-低GC的疗效.
结论:
- 特拉斯图祖马布德鲁克斯泰坎代表了对HER2阳性胃癌的有前途的进展,特别是在耐火环境中.
- 解决耐药机制和探索新的HER2导向疗法对于改善患者的治疗结果至关重要.
- 未来的研究应该专注于优化更广泛的患者群体的治疗策略,包括那些HER2-低表达的患者.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:30Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
02:38Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K